论文部分内容阅读
对30例血糖控制在理想水平合并高血压的患者进行为期6周的厄贝沙坦治疗,分析比较治疗前后收缩压(SBP)、舒张压(DBP)、24h尿UMA、24h尿TP的变化。结果:厄贝沙坦150mg治疗2周后SBP、DBP较治疗前明显下降(P<0.01),血压达标率46.7%。未达标者继续予厄贝沙坦300mg治疗2周,SBP、DBP较2周时明显下降(P<0.001),血压达标率86.7%,6周时复查24h尿UMA、24h尿TP较治疗前明显下降(P<0.01)。结论:厄贝沙坦可明显降低2型糖尿病的SBP、DBP,呈剂量依赖,并且具有降低蛋白尿、保护肾脏的作用。本药耐受性好,没有不良事件发生。
30 patients with glycemic control at the ideal level with hypertension were treated with irbesartan for 6 weeks. The changes of SBP, DBP, 24h urinary UMA and 24h urinary TP were compared and analyzed. Results: The SBP and DBP in irbesartan 150 mg group decreased significantly (P <0.01) two weeks after treatment, and the blood pressure compliance rate was 46.7%. SBP and DBP were significantly lower than those at 2 weeks (P <0.001), blood pressure compliance rate was 86.7%, urinary UMA at 24 weeks and 24h urinary TP were significantly higher than those before treatment Decreased (P <0.01). Conclusion: Irbesartan can significantly reduce SBP and DBP in type 2 diabetes mellitus in a dose-dependent manner. It also has the effect of reducing proteinuria and protecting kidneys. The drug is well tolerated and no adverse events occur.